Boardroom Alpha
Boardroom Alpha
HRMY · Additional Proxy Materials (DEFA14A) · Filed April 3, 2026

Harmony Biosciences Holdings Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 3, 2026
Ticker
HRMY
Accession
0001104659-26-039453
Boardroom Alpha · Filing insights

Harmony Biosciences urges voting FOR its four directors, Deloitte audit ratification, and the executive compensation advisory vote.

About Harmony Biosciences Holdings Inc
Market cap
$1.8B
1Y TSR
−7.5%
3Y TSR
−4.6%
Board grade
C+
Sector
Healthcare
CEO
Jeffrey M Dayno
Last annual meeting: May 14, 2026 · View full Harmony Biosciences Holdings Inc profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934


Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to 240.14a-11(c) or 240.14a-2

Harmony Biosciences Holdings, Inc.

(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


GRAPHIC

Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V89931-P48489 HARMONY BIOSCIENCES HOLDINGS, INC. 630 WEST GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING, PA 19462 HARMONY BIOSCIENCES HOLDINGS, INC. You invested in HARMONY BIOSCIENCES HOLDINGS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 14, 2026. Vote Virtually at the Meeting* May 14, 2026 1:00 p.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/HRMY2026 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 30, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. 2026 Annual Meeting Vote by May 13, 2026 11:59 PM ET

GRAPHIC

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V89932-P48489 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. The election of four Class III directors to serve until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified. For Nominees: 01) Geno J. Germano 02) Troy Ignelzi 03) Ron Philip 04) Andreas Wicki, Ph.D. 2. Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. For 3. Non-binding, advisory vote on the compensation of our named executive officers pursuant to the SEC’s compensation disclosure rules. For NOTE: To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Harmony Biosciences Holdings Inc (HRMY)

Reference

Frequently asked questions

When did Harmony Biosciences Holdings Inc file this DEFA14A?
Harmony Biosciences Holdings Inc (HRMY) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 3, 2026. The accession number assigned by EDGAR is 0001104659-26-039453.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Harmony Biosciences urges voting FOR its four directors, Deloitte audit ratification, and the executive compensation advisory vote. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Harmony Biosciences Holdings Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Harmony Biosciences Holdings Inc has filed under CIK 1802665, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer